Pulmonary arterial hypertension

Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro

Keros Therapeutics Halts Higher Dose Arms in PAH Trial Due to Pericardial Effusion Concerns

4 months ago talkbio0Tagged clinical trial safety, KER-012, Pericardial effusion, Pulmonary arterial hypertension, TROPOS

Keros Therapeutics, TROPOS trial, pulmonary arterial hypertension (PAH), cibotercept (KER-012), pericardial effusion, clinical trial safety

Keros Therapeutics Faces Major Setback as PAH Trial Dosing Suspended Over Safety Concerns

4 months ago talkbio0Tagged concerns, dosing, KER-012, PAH, Phase II TROPOS trial, Pulmonary arterial hypertension, Safety, Suspensions

Keros Therapeutics, PAH trial, dosing suspension, safety concerns, pulmonary arterial hypertension, cibotercept (KER-012), Phase II TROPOS trial

Merck’s Winrevair Demonstrates Significant Mortality Benefit in Pulmonary Arterial Hypertension Patients

5 months ago talkbio0Tagged Benefit, Co., Mortality Vital Statistics, PAH, Pulmonary arterial hypertension, Sotatercept, Winrevair

Winrevair, Pulmonary Arterial Hypertension (PAH), Mortality Benefit, Sotatercept, Merck & Co.

Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study

5 months ago talkbio0Tagged Cardiovascular system, Merck, Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III, Pulmonary arterial hypertension, Winrevair, ZENITH study

Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality

Advancements in Pulmonary Hypertension and Interstitial Lung Disease: Emerging Therapies and Clinical Trial Designs

6 months ago talkbio0Tagged Clinical Trials, diagnostic tools, Lung Diseases, Interstitial, Pathogenesis, Phenotype, Pulmonary arterial hypertension, Pulmonary Hypertension

Pulmonary Hypertension (PH), Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH), Clinical Trials, Emerging Therapies, Pathogenesis, Phenotypes, Diagnostic Tools

Cereno’s CS1 Shows Promising Results in Reducing PAH Risks in Phase 2 Trial

7 months ago talkbio0Tagged Cereno, disease-modifying, Epigenetic modulation, HDAC9 gene, Inhibitor, Phase 2 trial, Pulmonary arterial hypertension, Science, SLAMF7 protein, human

Cereno Scientific, CS1, HDAC inhibitor, Pulmonary Arterial Hypertension (PAH), Phase 2 trial, Epigenetic modulation, CardioMEMS HF System, Disease-modifying treatment